DESVENLAFAXINE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Desvenlafaxine, and what generic alternatives are available?
Desvenlafaxine is a drug marketed by Alembic Pharms Ltd, Sun Pharm, Teva Pharms Usa, Actavis Labs Fl, Alembic, Hikma, Intellipharmaceutics, Lupin Ltd, Norvium Bioscience, Rubicon, Yichang Humanwell, and Zydus Pharms. and is included in thirteen NDAs.
The generic ingredient in DESVENLAFAXINE is desvenlafaxine succinate. There are sixteen drug master file entries for this compound. Twenty-two suppliers are listed for this compound. Additional details are available on the desvenlafaxine succinate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Desvenlafaxine
A generic version of DESVENLAFAXINE was approved as desvenlafaxine succinate by ALEMBIC on June 29th, 2015.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for DESVENLAFAXINE?
- What are the global sales for DESVENLAFAXINE?
- What is Average Wholesale Price for DESVENLAFAXINE?
Summary for DESVENLAFAXINE
| US Patents: | 0 |
| Applicants: | 12 |
| NDAs: | 13 |
| Finished Product Suppliers / Packagers: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 122 |
| Clinical Trials: | 71 |
| Patent Applications: | 2,579 |
| Drug Prices: | Drug price information for DESVENLAFAXINE |
| What excipients (inactive ingredients) are in DESVENLAFAXINE? | DESVENLAFAXINE excipients list |
| DailyMed Link: | DESVENLAFAXINE at DailyMed |
Recent Clinical Trials for DESVENLAFAXINE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Universidade do Extremo Sul Catarinense - Unidade Academica de Ciecias da Saude | Phase 2 |
| Sage Therapeutics | Phase 3 |
| CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Phase 3 |
Pharmacology for DESVENLAFAXINE
Anatomical Therapeutic Chemical (ATC) Classes for DESVENLAFAXINE
US Patents and Regulatory Information for DESVENLAFAXINE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Yichang Humanwell | DESVENLAFAXINE SUCCINATE | desvenlafaxine succinate | TABLET, EXTENDED RELEASE;ORAL | 210014-002 | Oct 1, 2018 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Zydus Pharms | DESVENLAFAXINE SUCCINATE | desvenlafaxine succinate | TABLET, EXTENDED RELEASE;ORAL | 204020-003 | Nov 30, 2022 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Alembic Pharms Ltd | DESVENLAFAXINE | desvenlafaxine | TABLET, EXTENDED RELEASE;ORAL | 204150-001 | Mar 4, 2013 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
